Study of Sac-TMT in Early High-Risk Breast Cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests a new drug called Sacituzumab Tirumotecan (Sac-TMT) for people with early-stage, high-risk breast cancer that hasn't spread. The drug is given before surgery to see if it can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have early-stage breast cancer (not spread to distant organs) that is at high risk
- Your cancer must be either triple-negative or HR-low (having low levels of hormone receptors) and HER2-negative
- You must be willing to provide a biopsy of your breast tumor for testing
- You should be generally active (able to do light housework or office work)
- You must not have received any treatment for this breast cancer yet (including surgery, chemo, or radiation)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new drugs (sacituzumab tirumotecan and pembrolizumab) against standard treatments for a type of advanced breast cancer that is hormone receptor positive and HER2 negative. It's for people whose cancer has worsened despite hormone therapy with a CDK4/6 inhibitor.
This trial tests a new drug, Sac-TMT, given alone or with an immunotherapy drug (pembrolizumab) for people with advanced triple-negative breast cancer who have not yet received any treatment for advanced disease. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial is testing a new drug called Sac-TMT for people with advanced ovarian cancer that has not responded well to initial platinum-based chemotherapy and does not have a specific gene change called HRD. It aims to see if this drug can work better than standard treatment.
This trial tests a new drug called Sac-TMT for people with advanced squamous cell carcinoma of the vagina or vulva that has spread or cannot be cured with standard treatments. The drug targets a protein on cancer cells to deliver chemotherapy directly to the tumor, potentially slowing or stopping its growth.
This trial tests a new sequence of drugs (Sac-TMT followed by capecitabine) versus capecitabine alone for people with early-stage, high-risk triple-negative breast cancer who do not have BRCA mutations. It aims to see if the added treatment helps prevent the cancer from coming back.
This study tests a combination of two drugs—Sacituzumab Tirumotecan (Sac-TMT) and an immunotherapy called KL-A167—given before surgery to shrink triple-negative breast tumors. It aims to improve outcomes for people with early-stage, high-risk breast cancer who have not yet had any treatment.
Hear when a new Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.